Brian Park, PharmD

Findings showed that the booster dose elicited robust antibody responses comparable to, or exceeding levels associated with the efficacy data in the primary series of the vaccine.

The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.

In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.

The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy.

Basimglurant is a potent, cell-penetrant negative allosteric modulator of mGlu5 receptors that works by lowering the perception of pain threshold.

The FDA cleared the device based on data from a placebo-controlled, randomized, double-blind, parallel group clinical study.

Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.

Approval was based on a prospective study that evaluated the effectiveness of the Primary Relief device in 60 patients who underwent cardiac surgery.

SP-103 is a next generation triple strength formulation of ZTlido (lidocaine topical system) 1.8%.

The final rule takes effect in 60 days and consumers will be able to purchase hearing aids directly from stores or online retailers as soon as mid-October.